Proteros Biostructures

Proteros Biostructures is a private, revenue-generating contract research organization (CRO) specializing in high-value, early-stage drug discovery services for the global pharmaceutical and biotechnology industry. Founded in 1999 and rooted in Nobel Prize-winning science from the Max-Planck Institute, the company has built a strong reputation for tackling 'high hanging fruit' targets like membrane proteins and multi-subunit complexes. Through its integrated technology platform and collaborative 'REACH RIGHT FASTER' approach, Proteros aims to de-risk and accelerate client programs, positioning itself as a strategic partner in a growing outsourced discovery market.

Integrated early drug discovery platform specializing in technically challenging targets ('high hanging fruits'). Core capabilities include protein science (producing the 'RIGHT' protein), structural biology (X-ray crystallography and cryo-EM), assay development & biophysics, biologics characterization, and screening. Enables 'target-to-qualified hits' programs.

Proteros competes in the drug discovery services market against large, full-service CROs (e.g., Charles River, Evotec, LabCorp) and specialized structural biology/biophysics boutiques. Its key differentiator is a deep focus on technically challenging, structure-enabled discovery for 'high hanging fruit' targets, combining Nobel-prize rooted scientific excellence with an agile, partnership-oriented service model.